News

The randomised, placebo controlled Phase I study is intended to assess the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944. Recently, ascending dose Phase

The ascending dose, double-blind, placebo-controlled study in healthy, non-smoking and smoking volunteers is designed to demonstrate the safety, tolerability and pharmacodynamic profile of the drug candidate. The study

The new approach combines synthetic chemistry with advanced screening technologies which would expand the number of provocative synthetic compounds available to explore as potential drug candidates. In addition,

Dexpramipexole, initially developed by Knopp Biosciences, is a novel drug which prevents dysfunction of mitochondria, the subcellular structures that provide most of a cell’s energy. The researchers devised

T89, also known as Dantonic pill, is a botanical product used to treat chronic stable angina pectoris due to coronary heart disease and aims to become the first

Erwinaze is an asparaginase enzyme which depletes asparagine level in the bloodstream. Asparagine helps in cell growth, and its removal from the blood inhibits the growth of cells

Under the terms of the agreement, Valeant will pay iNova shareholders A$625m ($623.39) upfront and up to an additional A$75m ($74.81) in potential milestones. Valeant Pharmaceuticals develops, manufactures

The deal is expected to strengthen Lupin’s presence in the Japanese market. Lupin president (Asia Pacific, Middle East, Africa and Latin America) Vinod Dhawan said the acquisition would

TNX-102 is a bedtime gelcap with very low dose cyclobenzaprine, which aids in faster and improved absorption as compared to conventional cyclobenzaprine products. The single-dose open-label randomised three-way-crossover